Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation

dc.contributor.authorGalindo Camacho, Ruth Milagros
dc.contributor.authorSánchez-López, E. (Elena)
dc.contributor.authorGómara Elena, María José
dc.contributor.authorEspina García, Marta
dc.contributor.authorEttcheto Arriola, Miren
dc.contributor.authorCano Fernández, Amanda
dc.contributor.authorHaro Villar, Isabel
dc.contributor.authorCamins Espuny, Antoni
dc.contributor.authorGarcía López, María Luisa
dc.date.accessioned2022-03-03T07:01:23Z
dc.date.available2022-03-03T07:01:23Z
dc.date.issued2022-01-26
dc.date.updated2022-03-03T07:01:24Z
dc.description.abstractLicochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Additionally, to avoid fast clearance and increase cellular internalization into the ocular tissues, PLGA nanoparticles have been functionalized using PEG and cell penetrating peptides (Tet-1 and B6). To optimize the formulations, a factorial design was carried out and short-term stability of the nanoparticles was studied. Moreover, morphology was also observed by transmission electron microcopy and in vitro drug release was carried out. Ocular tolerance of the formulations was ensured in vitro and in vivo and anti-inflammatory therapeutic efficacy was also assessed. Surface functionalized nanoparticles loading Licochalcone-A were developed with an average size below 200 nm, a positive surface charge, and a monodisperse population. The formulations were non-irritant and showed a prolonged Licochalcone-A release. Despite the fact that both Licochalcone-A Tet-1 and B6 functionalized nanoparticles demonstrated to be suitable for the treatment of ocular inflammation, B6 targeted nanoparticles provided greater therapeutic efficacy in in vivo assays. Keywords: Licochalcone-A; nanoparticles; ocular inflammation; cell-penetrating peptides; PLGA
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec717860
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/2445/183714
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics14020285
dc.relation.ispartofPharmaceutics, 2022, vol. 14, p. 285
dc.relation.urihttps://doi.org/10.3390/pharmaceutics14020285
dc.rightscc-by (c) Galindo, Ruth et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationFarmacologia ocular
dc.subject.classificationPèptids
dc.subject.classificationNanopartícules
dc.subject.classificationAgents antiinflamatoris
dc.subject.otherOcular pharmacology
dc.subject.otherPeptides
dc.subject.otherNanoparticles
dc.subject.otherAntiinflammatory agents
dc.titleDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
717860.pdf
Mida:
3.29 MB
Format:
Adobe Portable Document Format